High Cholesterol

National Lipid Association statin study shows liver monitoring is unnecessary

Published in Medical Letter on the CDC and FDA, May 10th, 2006

In the most comprehensive, rigorous, non-governmental analysis of statins ever undertaken, the National Lipid Association (NLA) confirmed the safety profile and benefits of cholesterol-lowering statin therapy and concluded that requirements to monitor patients' liver function are no longer necessary.

In addition, the NLA recommends a review of these requirements by the U.S. Food & Drug Administration (FDA) and others.

"The problem is not that too many patients are having too many side effects. The problem is that too many patients are not being treated to reduce their risk of heart disease - the number one killer of both men and women in the United...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry